Autoinducer-2 of gut microbiota, a potential novel marker for human colorectal cancer, is associated with the activation of TNFSF9 signaling in macrophages. (3rd October 2019)

• Record Type: Journal Article
• Authors: Li, Qing; Peng, Wei; Wu, Jiao; Wang, Xianfei; Ren, Yixing; Li, Huan; Peng, Yan; Tang, Xiaowei; Fu, Xiangsheng
• Is Part Of: Oncoimmunology. Volume 8:Number 10(2019)
• Publication Date: 2019-10-03
• Subjects: Autoinducer-2 -- gut microbiota -- fusobacterium nucleatum -- macrophages -- colorectal cancer -- immune; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2019.1626192
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Objectives : The interaction between the quorum sensing (QS) molecules of gut microbiota and the immunity of colorectal cancer (CRC) has not been investigated before. Methods : We measured the concentration of autoinducer-2 (AI-2) in samples of stool, colorectal tissue, saliva and serum of CRC patients, and compared this to AI-2 levels in colorectal adenoma (AD) and normal colon mucosa (NC). To explore the activated signaling pathways involved, we utilized AI-2 extracted from Fusobacterium nucleatum to stimulate macrophages and validated these in vitro findings in human CRC tissues. Results : The AI-2 concentration in both colorectal tissue and stool of CRC patients was significantly higher when compared to that in AD and NC (all P values < .01). The AI-2 concentration along with the progression of CRC in both tissues and stools was significantly increased ( P = .045， P = .0003, respectively). After AI-2 stimulation, TNFSF9 was the most significantly increased protein in macrophage cells ( P < .01). TNFSF9 expression was significantly higher in CRC tissues when compared to NCs ( P < .0001), which was mainly derived from macrophages in the tumor microenvironment. Moreover, AI-2 level was positively associated with CD3 + T cell numbers ( P = .0462), and negatively associated with CD4/CD8 ratio ( P = .0113) within CRC tissues. Conclusions : We demonstrated for the first time that AI-2 may serve as a novel marker for screening CRC in the clinic. AI-2 was associated with tumor immunity in CRCs through tumor-associated macrophages and CD4/CD8 ratio in a TNFSF9-dependent manner.